- Home
- COEP vs ANEB Comparison
COEP vs ANEB Comparison
Compare COEP & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- ANEB
- Stock Information
- Founded
- COEP 2017
- ANEB 2020
- Country
- COEP United States
- ANEB United States
- Employees
- COEP N/A
- ANEB N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- ANEB Biotechnology: Pharmaceutical Preparations
- Sector
- COEP Health Care
- ANEB Health Care
- Exchange
- COEP Nasdaq
- ANEB Nasdaq
- Market Cap
- COEP 86.0M
- ANEB 111.8M
- IPO Year
- COEP N/A
- ANEB 2021
- Fundamental
- Price
- COEP $15.00
- ANEB $2.74
- Analyst Decision
- COEP
- ANEB Buy
- Analyst Count
- COEP 0
- ANEB 2
- Target Price
- COEP N/A
- ANEB $8.00
- AVG Volume (30 Days)
- COEP 46.4K
- ANEB 28.4K
- Earning Date
- COEP 11-12-2025
- ANEB 11-12-2025
- Dividend Yield
- COEP N/A
- ANEB N/A
- EPS Growth
- COEP N/A
- ANEB N/A
- EPS
- COEP N/A
- ANEB N/A
- Revenue
- COEP $263,555.00
- ANEB N/A
- Revenue This Year
- COEP N/A
- ANEB N/A
- Revenue Next Year
- COEP N/A
- ANEB N/A
- P/E Ratio
- COEP N/A
- ANEB N/A
- Revenue Growth
- COEP N/A
- ANEB N/A
- 52 Week Low
- COEP $2.31
- ANEB $0.80
- 52 Week High
- COEP $19.19
- ANEB $3.42
- Technical
- Relative Strength Index (RSI)
- COEP 47.09
- ANEB 63.78
- Support Level
- COEP $14.59
- ANEB $2.50
- Resistance Level
- COEP $16.17
- ANEB $2.85
- Average True Range (ATR)
- COEP 0.90
- ANEB 0.15
- MACD
- COEP -0.33
- ANEB 0.04
- Stochastic Oscillator
- COEP 8.29
- ANEB 82.26
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.